Insider & Cluster Buy Highlights – December 22, 2025
📅 Published: December 22, 2025 at 01:01 PM UTC
5 Cluster Buys5 Insider Purchases
On December 22, 2025, this newsletter featured 5 cluster buys and 5 insider purchases detected from SEC Form 4 filings.
📈 Daily Insider & Cluster Buy Highlights – December 22, 2025
Here are some of the most interesting insider and cluster buying signals from the last 7 days.
⚠️ For information purposes only.
This information is provided for informational purposes only and does not constitute investment advice, financial advice, trading advice, or any other type of advice. All investments carry risk, including the potential loss of principal. Past performance is not indicative of future results. You should consult with a qualified financial advisor, accountant, or other professional before making any investment decisions. The information contained in this newsletter is not intended to be a substitute for professional financial advice.
📊 About Fair Value:
The Fair Value shown for each company is calculated using a Levered Discounted Cash Flow (DCF) model. This method estimates the intrinsic value of a stock by projecting future cash flows and discounting them back to present value, accounting for the company's debt structure. A positive percentage difference indicates the stock may be undervalued relative to this model, while a negative percentage suggests it may be overvalued. Fair value calculations are estimates and should be considered alongside other factors.
🔥 Notable Cluster Buys (≥ $500,000)
Seven Hills Realty TrustView Chart
Ticker: RMRM
$10.31
Current Price
52W: Low: $7.78 | High: $13.64
Participants: 2 insiders
Total Shares: 4,031,496
Total Value: $34,872,440
Timeframe: 0 days
Date Range: Dec 11, 2025 to Dec 11, 2025
👥 Participant Details:
Tremont Realty Capital LLC
10% Owner
Date: Dec 11, 2025
2,015,748 shares
$17,436,220
@ $8.65/share
P&L: +19.2% (+$3,346,142)
PORTNOY ADAM D.
Director
Date: Dec 11, 2025
2,015,748 shares
$17,436,220
@ $8.65/share
P&L: +19.2% (+$3,346,142)
📈
Average P&L: 19.2% ($3,346,142 gain)
Verrica Pharmaceuticals IncView Chart
Ticker: VRCA
$7.82
Current Price
52W: Low: $3.28 | High: $9.82
Participants: 5 insiders
Total Shares: 1,485,584
Total Value: $6,302,590
Timeframe: 0 days
Date Range: Nov 25, 2025 to Nov 25, 2025
👥 Participant Details:
Zawitz David
Date: Nov 25, 2025
10,000 shares
$42,425
@ $4.24/share
P&L: +84.3% (+$35,775)
Manning Paul B
Date: Nov 25, 2025
1,375,380 shares
$5,835,050
@ $4.24/share
P&L: +84.3% (+$4,920,422)
Rieger Jayson
Date: Nov 25, 2025
94,311 shares
$400,114
@ $4.24/share
P&L: +84.3% (+$337,398)
Kirby John J.
Date: Nov 25, 2025
3,536 shares
$15,001
@ $4.24/share
P&L: +84.3% (+$12,650)
Rosenberg Noah L.
Date: Nov 25, 2025
2,357 shares
$10,000
@ $4.24/share
P&L: +84.3% (+$8,432)
📈
Average P&L: 84.3% ($1,062,935 gain)
Analyst Coverage:
Analyst Rating: C
Avg Price Target: $17.00 (+117.4% vs current)
ALUMIS INCView Chart
Ticker: ALMS
$11.29
Current Price
52W: Low: $2.76 | High: $12.44
$4.90
Fair Value
Participants: 4 insiders
Total Shares: 342,379
Total Value: $2,504,123
Timeframe: 1 days
Date Range: Nov 20, 2025 to Nov 21, 2025
👥 Participant Details:
AKKARAJU SRINIVAS
Date: Nov 20, 2025
125,743 shares
$905,350
@ $7.20/share
P&L: +56.8% (+$514,289)
Tananbaum James B.
Director
Date: Nov 21, 2025
72,212 shares
$532,925
@ $7.38/share
P&L: +53.0% (+$282,349)
Foresite Capital Management VI LLC
10% Owner
Date: Nov 21, 2025
72,212 shares
$532,925
@ $7.38/share
P&L: +53.0% (+$282,349)
Foresite Labs, LLC
10% Owner
Date: Nov 21, 2025
72,212 shares
$532,925
@ $7.38/share
P&L: +53.0% (+$282,349)
📈
Average P&L: 53.9% ($340,334 gain)
Valuation Metrics:
Fair Value: $4.90 (56.6% overvalued vs current price)
Analyst Coverage:
Analyst Rating: C+
Avg Price Target: $20.00 (+77.1% vs current)
Hoyne Bancorp, IncView Chart
Ticker: HYNE
$13.70
Current Price
52W: Low: $13.35 | High: $14.25
Participants: 10 insiders
Total Shares: 185,900
Total Value: $1,859,000
Timeframe: 0 days
Date Range: Dec 03, 2025 to Dec 03, 2025
👥 Participant Details:
Opas David M.
Director
Date: Dec 03, 2025
10,000 shares
$100,000
@ $10.00/share
P&L: +37.0% (+$37,000)
Breems Timothy S
Director
Date: Dec 03, 2025
15,000 shares
$150,000
@ $10.00/share
P&L: +37.0% (+$55,500)
Gonsch Judith A.
Director
Date: Dec 03, 2025
30,000 shares
$300,000
@ $10.00/share
P&L: +37.0% (+$111,000)
Vaccarello Anthony M.
Director
Date: Dec 03, 2025
10,000 shares
$100,000
@ $10.00/share
P&L: +37.0% (+$37,000)
Wiemann Theodore C.
Director
Date: Dec 03, 2025
25,000 shares
$250,000
@ $10.00/share
P&L: +37.0% (+$92,500)
Healy Walter F
Director
Date: Dec 03, 2025
23,925 shares
$239,250
@ $10.00/share
P&L: +37.0% (+$88,522)
Carstensen Paula M.
Director
Date: Dec 03, 2025
20,000 shares
$200,000
@ $10.00/share
P&L: +37.0% (+$74,000)
Manfre Thomas S.
Officer
Date: Dec 03, 2025
1,975 shares
$19,750
@ $10.00/share
P&L: +37.0% (+$7,307)
Rosenbaum Steven F.
Director
Date: Dec 03, 2025
30,000 shares
$300,000
@ $10.00/share
P&L: +37.0% (+$111,000)
Winningham Janet H.
Director
Date: Dec 03, 2025
20,000 shares
$200,000
@ $10.00/share
P&L: +37.0% (+$74,000)
📈
Average P&L: 37.0% ($68,783 gain)
Analyst Coverage:
Analyst Rating: D+
Central Bancompany, IncView Chart
Ticker: CBC
$23.40
Current Price
52W: Low: $22.50 | High: $25.00
Participants: 17 insiders
Total Shares: 233,987
Total Value: $4,913,727
Timeframe: 0 days
Date Range: Nov 21, 2025 to Nov 21, 2025
👥 Participant Details:
KRUSE CHARLES E
Director
Date: Nov 21, 2025
2,500 shares
$52,500
@ $21.00/share
P&L: +11.4% (+$6,000)
Robuck Robert Marion
Director
Date: Nov 21, 2025
47,619 shares
$999,999
@ $21.00/share
P&L: +11.4% (+$114,286)
Schoeneberg Carey Denise
Officer
Date: Nov 21, 2025
1,000 shares
$21,000
@ $21.00/share
P&L: +11.4% (+$2,400)
Kellett Scott McKinney
Officer
Date: Nov 21, 2025
1,000 shares
$21,000
@ $21.00/share
P&L: +11.4% (+$2,400)
Cook Sam Bryan
Director
Date: Nov 21, 2025
38,619 shares
$810,999
@ $21.00/share
P&L: +11.4% (+$92,686)
Hallgren Eric Andrew
Officer
Date: Nov 21, 2025
2,500 shares
$52,500
@ $21.00/share
P&L: +11.4% (+$6,000)
Ciroli James
Officer
Date: Nov 21, 2025
17,000 shares
$357,000
@ $21.00/share
P&L: +11.4% (+$40,800)
Hermann Robert Ringen Jr.
Director
Date: Nov 21, 2025
47,619 shares
$999,999
@ $21.00/share
P&L: +11.4% (+$114,286)
Ross John Thomas
Director
Date: Nov 21, 2025
42,000 shares
$882,000
@ $21.00/share
P&L: +11.4% (+$100,800)
Digges Charles William Jr.
Director
Date: Nov 21, 2025
5,000 shares
$105,000
@ $21.00/share
P&L: +11.4% (+$12,000)
McClure Richard Hays
Director
Date: Nov 21, 2025
11,200 shares
$235,200
@ $21.00/share
P&L: +11.4% (+$26,880)
Robertson Edward Deroy Jr.
Director
Date: Nov 21, 2025
4,550 shares
$95,550
@ $21.00/share
P&L: +11.4% (+$10,920)
Colbert Jeremy Wayne
Officer
Date: Nov 21, 2025
2,200 shares
$46,200
@ $21.00/share
P&L: +11.4% (+$5,280)
Westhues Daniel Harold
Officer
Date: Nov 21, 2025
4,200 shares
$88,200
@ $21.00/share
P&L: +11.4% (+$10,080)
Goldammer Russell Lee
Officer
Date: Nov 21, 2025
2,000 shares
$42,000
@ $21.00/share
P&L: +11.4% (+$4,800)
Sprong Bradley Nixon
Director
Date: Nov 21, 2025
4,500 shares
$94,500
@ $21.00/share
P&L: +11.4% (+$10,800)
Thompson Tristan Antin
Officer
Date: Nov 21, 2025
480 shares
$10,080
@ $21.00/share
P&L: +11.4% (+$1,152)
📈
Average P&L: 11.4% ($33,033 gain)
Analyst Coverage:
Avg Price Target: $28.75 (+22.9% vs current)
💼 Notable Individual Insider Buys (≥ $100,000)
$21.44
Current Price
$2.43
Fair Value
Transaction Date: Dec 18, 2025
Shares: 46,511
Purchase Price: $21.50
Purchase Value: $999,986
📉
P&L: 0.3% ($2,791 loss)
Valuation Metrics:
Fair Value: $2.43 (88.7% overvalued vs current price)
Analyst Coverage:
Analyst Rating: C
Avg Price Target: $36.20 (+68.8% vs current)
📰 Recent News (Last 7 Days):
Seeking Alpha • Dec 17, 2025
Immunome (IMNM) delivered statistically significant phase 3 RINGSIDE results for varegacestat in progressive desmoid tumors, achieving an 84% risk reduction in progression or death compared to placebo...
Business Wire • Dec 16, 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced t...
Defense World • Dec 16, 2025
Immunome, Inc. (NASDAQ: IMNM - Get Free Report) was the recipient of unusually large options trading activity on Monday. Traders acquired 2,906 call options on the stock. This represents an increase o...
The Motley Fool • Dec 15, 2025
A phase 3 study of varegacestat met its primary endpoint. The drug candidate could reduce the risk of disease progression or death in people with desmoid tumors by 84%.
Business Wire • Dec 15, 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced i...
Investors Business Daily • Dec 15, 2025
Top-notch biotech stock Immunome rocketed Monday after the company's treatment for desmoid tumors appeared to top an approved drug.
Reuters • Dec 15, 2025
Immunome said on Monday its experimental drug met main goal in a late-stage study for patients with a rare type of tumor.
Business Wire • Dec 15, 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive top...
$259.91
Current Price
$224.57
Fair Value
Transaction Date: Dec 17, 2025
Shares: 1,936
Purchase Price: $258.64
Purchase Value: $500,722
📈
P&L: 0.5% ($2,464 gain)
Valuation Metrics:
Fair Value: $224.57 (13.6% overvalued vs current price)
Analyst Coverage:
Analyst Rating: B+
Avg Price Target: $310.00 (+19.3% vs current)
📰 Recent News (Last 7 Days):
Defense World • Dec 21, 2025
CHICAGO TRUST Co NA trimmed its position in Salesforce Inc. (NYSE: CRM) by 31.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commi...
Defense World • Dec 21, 2025
Douglas Lane and Associates LLC grew its holdings in shares of Salesforce Inc. (NYSE: CRM) by 25.4% in the undefined quarter, according to the company in its most recent disclosure with the Securities...
Defense World • Dec 20, 2025
Central Bank and Trust Co. cut its holdings in shares of Salesforce Inc. (NYSE: CRM) by 31.4% in the undefined quarter, according to the company in its most recent disclosure with the Securities and E...
Defense World • Dec 20, 2025
Bartlett and CO. Wealth Management LLC increased its position in Salesforce Inc. (NYSE: CRM) by 2.6% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund...
The Motley Fool • Dec 19, 2025
Palantir's valuation levels are far too high. AMD believes it can grow at a rapid pace.
Seeking Alpha • Dec 19, 2025
My 2025 picks outperformed the S&P 500 by 9.4% and Nasdaq 100 by 5.9%, validating my growth-value approach. Each stock on this list is operating in a different market segment and two are based in Euro...
Zacks Investment Research • Dec 19, 2025
Salesforce.com (CRM) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Benzinga • Dec 18, 2025
Salesforce Inc (NYSE: CRM) is being valued like a mature enterprise software name just as artificial intelligence begins to reshape how its platform is used — and monetized. JPMorgan argues that the d...
Yahoo Finance • Dec 18, 2025
Market Catalysts anchor Julie Hyman breaks down the latest market news for December 18, 2025.Yahoo Finance senior reporter Brooke DiPalma tracks several Wall Street analyst calls on top trending stock...
Barrons • Dec 17, 2025
Investors should consider cheaper AI names that haven't surged as much over the years.
Business Wire • Dec 17, 2025
SAN FRANCISCO--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world's #1 AI CRM, announced today that Novartis (NYSE: NVS), a leading global innovative medicines company, has selected Salesforce's Agent...
247 Wallst • Dec 17, 2025
Pre-Market Stock Futures: Futures are trading higher on Wednesday as we reach the midpoint of the last full trading week of the year. Sellers once again took their toll on two of the major indices, wh...
GuruFocus • Dec 17, 2025
Stock News WBD backs Netflix, rejects PSKY bid: Warner Bros. Discovery (WBD) urged shareholders to reject Paramount Skydance's (PSKY) $30-per-share hostile tend
MarketBeat • Dec 16, 2025
Insider trades are often some of the most revealing signals in the market—and three recent moves are sending sharply different messages. At Salesforce NYSE: CRM, a board member is doubling down after ...
GuruFocus • Dec 16, 2025
Stock News Ford pivots from pure EVs, takes $19.5B charge: Ford Motor (F) will record about $19.5 billion in special items tied to a pullback from all-electric
Seeking Alpha • Dec 15, 2025
For 3Q25, Macquarie Core Equity Fund Institutional Class shares underperformed the Fund's benchmark, the S&P 500 Index. Cummins Inc. saw steady share price gains and positive momentum due to strong re...
🏛️ Senate Trading Activity (Past 2 Months):
John Boozman (AR) - Sale
Date: Nov 13, 2025 | Amount: $1,001 - $15,000 | Owner: Joint
John Boozman (AR) - Sale (Full)
Date: Nov 13, 2025 | Amount: $1,001 - $15,000 | Owner: Joint
🏛️ House Trading Activity (Past 2 Months):
Tony Wied (WI08) - Purchase
Date: Oct 27, 2025 | Amount: $100,001 - $250,000 | Owner: Joint
$19.28
Current Price
$18.25
Fair Value
Transaction Date: Dec 17, 2025
Shares: 20,000
Purchase Price: $17.83
Purchase Value: $356,576
📈
P&L: 8.1% ($29,024 gain)
Valuation Metrics:
Fair Value: $18.25 (5.4% overvalued vs current price)
Analyst Coverage:
Analyst Rating: C
Avg Price Target: $28.00 (+45.2% vs current)
📰 Recent News (Last 7 Days):
Defense World • Dec 21, 2025
Hallador Energy Company (NASDAQ: HNRG - Get Free Report) Director Charles Ray Iv Wesley acquired 20,000 shares of the firm's stock in a transaction dated Wednesday, December 17th. The stock was bought...
Zacks Investment Research • Dec 19, 2025
MDB, HNRG and IVZ made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Dec. 19, 2025.
Zacks Investment Research • Dec 19, 2025
PSX, MDB, HNRG, SPNT and JBSS have been added to the Zacks Rank #1 (Strong Buy) List on Dec. 19, 2025.
Seeking Alpha • Dec 18, 2025
Hallador Energy (HNRG) earns a buy rating for its integrated energy model and critical accredited capacity in the MISO grid. HNRG's vertical integration shields it from coal market volatility, enablin...
GlobeNewsWire • Dec 16, 2025
TERRE HAUTE, Ind., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Hallador Energy Company (Nasdaq: HNRG) (“Hallador” or the “Company”) today announced that the Company has finalized its application into the Expedi...
$5.64
Current Price
$21.21
Fair Value
Transaction Date: Dec 17, 2025
Shares: 44,208
Purchase Price: $5.50
Purchase Value: $243,144
📈
P&L: 2.5% ($6,189 gain)
Valuation Metrics:
Fair Value: $21.21 (276.0% undervalued vs current price)
Analyst Coverage:
Analyst Rating: B
$6.18
Current Price
Transaction Date: Dec 16, 2025
Shares: 39,044
Purchase Price: $6.18
Purchase Value: $241,378
📉
P&L: 0.0% ($86 loss)
Analyst Coverage:
Analyst Rating: B
Avg Price Target: $5.75 (-7.0% vs current)
📰 Recent News (Last 7 Days):
Seeking Alpha • Dec 20, 2025
Embrace cheap stocks: they offer the largest upside potential for capital gains. High-yielders trading low are great "stocking stuffers" for income. The strategy provides a strong yield today while wa...
⚠️ For information purposes only.
This information is provided for informational purposes only and does not constitute investment advice, financial advice, trading advice, or any other type of advice. All investments carry risk, including the potential loss of principal. Past performance is not indicative of future results. You should consult with a qualified financial advisor, accountant, or other professional before making any investment decisions. The information contained in this newsletter is not intended to be a substitute for professional financial advice.
Want to receive these newsletters in your inbox? Sign up here